The Latest

NOW AVAILABLE: For the Biologics for Psoriasis Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q2 2017.

Lilly’s Taltz became the promotional market leader during Q2 2017 with a campaign focused on efficacy, savings, and a theme targeting the emotional side of psoriasis. The Taltz $5 or $25 Program evolved into The Taltz Clear Access Program. Janssen announced that Tremfya would be coming soon to the market. Brands continued to focus more on specific patient types with AbbVie positioning Humira as having the first and only FDA-approved data for fingernail psoriasis. Amgen’s Enbrel launched a DTC campaign for pediatric psoriasis and an unbranded psoriasis awareness campaign. Pfizer introduced patients to Inflectra with the release of its first branded DTC promotion. Additional insights into marketing strategies and channel utilization are available in the full Q2 report.

Q2-2017-Biologics-for-Psori

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the Biologics for RA Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q2 2017.

A total of 87 new pieces were received for the Rheumatoid Arthritis market during the second quarter of 2017, noting a 13% increase from the previous quarter. Promotional volume attributed to Pfizer’s Xeljanz franchise captured 25% of the market’s total volume, enabling the brand to be noted as the product with the highest density of promotional messaging for the second time this year. Within the observational analysis, Pfizer noted the launch of its new “Unjection” consumer campaign for Xeljanz/Xeljanz XR, which highlights the products’ needleless administration option for RA patients. Also during this quarter, Sanofi Genzyme/Regeneron announced the FDA approval of their newest drug, Kevzara, for patients with moderately to severely active RA. Additional insights into marketing strategies and channel utilization are available in the full Q2 report.

Q2-2017-RA

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact: US Markets: Christine Alongi at Alongi@dtwresearch.com // Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the U.S. Antipsychotic Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q1 2017.

Allergan’s Vraylar was in the lead in terms of the proportion of the promotional distribution received, followed closely by Aristada from Alkermes. Sunovion also made a strong showing in terms of volume, as it announced Latuda’s approval for the treatment of adolescents with schizophrenia. Dosing and support were the two most common topics highlighted across brands, with some products providing support also intended for caregivers, including the More Than My Diagnosis website from the Otsuka Patient Education Network. Multiple savings offers and programs were made available in an effort to support patient access and treatment adherence, such as the Janssen Connect program. Promotions featured various campaign themes, mostly familiar, but new imagery was also noted from Vraylar and AstraZeneca’s Seroquel. Additional insights into marketing strategies and channel utilization are available in the full Q1 report.

Q1-2017-Antipsych

 

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the U.S. Antimigraine Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q1 2017.

Pfizer continued to be the leader in terms of promotional volume, producing a quarter of the materials received in support of Relpax, while Allergan came in for a close second as it increased promotions for Botox. The prevention market grew during this time period as Upsher-Smith’s Qudexy XR and Trokendi XR from Supernus each received final approval from the FDA for migraine prophylaxis. Avanir highlighted some migraine misconceptions alongside promotions for Onzetra Xsail, and Zembrace SymTouch from Promius Pharma emphasized the importance of treating multiple symptoms of migraine. Efficacy, supported by clinical trial data, was a common topic across brands, along with various offers of savings and support. Overall, HCPs were targeted more often than consumers and some brands favored e-media over print materials. Multiple campaign themes were featured, most of which were continued from previous time periods. Additional insights into marketing strategies and channel utilization are available in the full Q1 report.

Q1-2017-Antimigraine

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the Glucose Monitors Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q1 2017.

Overall, 62 new pieces were received for the glucose monitors market for this quarter, a significant increase from Q4, 2016. Dexcom distributed the most pieces, making up 24% of the market and promoting the “first of its kind” Dexcom G5 Mobile CGM System alongside a DTC campaign emphasizing fewer fingerpricks. Ascensia introduced new devices and resources, including the Contour Next One Smart Meter and App System, the Contour Next Concierge website, and updates to the Microlet Next lancing device. Roche announced the discontinuation of the Accu-Chek Safe-T-Pro professional lancing device, along with the launch of the Accu-Chek Safe-T Pro Uno, and the Accu-Chek Guide monitoring system. Medtronic premiered the MiniMed 630G system with SmartGuard technology safeguards and other convenient features. Patients were introduced to the Tandem Device Updater and the new t:slim X2 insulin pump. Pharmacists were given the opportunity to upgrade their patients from the OneTouch Ultra Meters to the OneTouch Verio Flex meter. Additional insights into marketing strategies and channel utilization are available in the full Q1 report.

Q1-2017-Glucose-Monitors

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the Biologics and Biosimilars for GI Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q1 2017.

Allergan’s Viberzi was the biologics and biosimilars for GI market leader in terms of promotional distribution between all brands observed, comprising 20% of the 70 new pieces received this quarter, and promoted the “Frustrating Symptoms” campaign alongside efficacy messages. UCB’s campaign for Cimzia presented patient profiles alongside efficacy and patient support with CIMplicity. Shire presented the “I Will” DTC campaign for Lialda, and highlighted features of the Lialda Patient Support Program. Janssen positioned Stelara as “a different kind of biologic,” emphasizing its clinical and patient experience. Salix’s Uceris presented the “Colon” campaign theme, which emphasized the product’s “colon-specific steroid power for complete UC relief.”  Additional insights into marketing strategies and channel utilization are available in the full Q1 report.

Q1-2017-GI

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the Multiple Myeloma Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q1 2017.

Takeda’s Ninlaro dominated the multiple myeloma market during this time period, producing 29% of the 59 new pieces received. Ninlaro presented the “Extend” campaign, which positioned Ninlaro as the first and only oral proteasome inhibitor and emphasized efficacy. Janssen’s Darzalex presented the “Discover” campaign, which emphasized Darzalex as “the first and only CD38-directed monoclonal antibody,” and continued to promote their latest indication. Amgen’s “Respond” campaign for Kyprolis emphasized superior progression-free survival. Celgene announced Revlimid’s new approval as maintenance therapy for multiple myeloma patients after autologous hematopoietic stem cell transplantation (auto-HSCT). Additional insights into marketing strategies and channel utilization are available in the full Q1 report.

Q1-2017-MM

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the U.S. Hemophilia Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q1 2017.

Novo Nordisk and Shire were highly competitive when it came to the volume of promotions received for their respective hemophilia products. Two new indications were announced by Shire for Adynovate, which included use in children under 12 and perioperative management. Bayer presented Kogenate FS as an alternative treatment after notifying healthcare professionals that CVS/Caremark would no longer cover Helixate FS and manufacturing of the product would cease at the end of the year. Novo Nordisk provided a satisfaction guarantee for Novoeight and announced peel-off labels for NovoSeven RT. E-media was extensively used by most products and the majority of materials overall were targeted toward healthcare professionals. Priority messages across brands continued to consist of those regarding product convenience and support for patients, including the promotion of March as Bleeding Disorders Awareness Month by Shire. Additional insights into marketing strategies and channel utilization are available in the full Q1 report.

Q1-2017-Hemophilia

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the U.S. Narcotic Analgesics Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q1 2017.

The majority of marketing materials continued to highlight the products’ abuse deterrent formulations, which discourage abuse as well as pharmacy theft. Pfizer released core materials promoting its brand Embeda as “the first and only ER morphine with sequestered naltrexone HCL,” which acts as an antagonist if the opioid is tampered with. Egalet Inc. noted that its product, Oxaydo, is the “first and only formulation of immediate-release oxycodone that discourages abuse via snorting.” Additionally, with the FDA approval of Arymo ER, Egalet announced the product’s co-pay card, which allows commercially insured patients to pay $0 for their first prescription. Additional insights into marketing strategies and channel utilization are available in the full Q1 report.

narc-2017

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact: US Markets: Christine Alongi at Alongi@dtwresearch.com \\ Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the Antidepressants Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q1 2017.

When taking a look at distributional volume between all brands, the majority of marketing materials were received for Pfizer’s Pristiq, comprising 21% of the 81 new pieces received this quarter. Pristiq emphasized formulary coverage, patient savings, and patient support in a number of physician-directed pieces. Otsuka continued to feature the “Make Way” campaign for Rexulti, with a tagline suggesting the brand offers “an option that may provide a combination of efficacy and safety to help reach treatment goals.” A new variation of AstraZeneca’s Seroquel XR “I’m OK” campaign encouraged healthcare professionals to stay together and “open up to the possibilities.” Takeda and Lundbeck continued to display the “Tangled” campaign to support Trintellix, which highlighted depression symptoms. Additional insights into marketing strategies and channel utilization are available in the full Q1 report.

Q1-2017-Antidepressants

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com